首页> 美国卫生研究院文献>Springer Open Choice >Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

【2h】

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

机译：Alemtuzumab-BEAM作为复发/难治性霍奇金淋巴瘤同种异体造血干细胞移植的条件：单中心分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Treatment of refractory Hodgkin disease deserves specific considerations. Recently, alemtuzumab-BEAM has been introduced in allogeneic hematopoietic stem cell transplantation (HSCT) in these patients.

机译：目的治疗难治性霍奇金病值得特别考虑。最近，在这些患者的同种异体造血干细胞移植（HSCT）中引入了alemtuzumab-BEAM。

著录项

期刊名称 Springer Open Choice
作者
W. Rabitsch; M. Bojic; P. Wohlfarth; M. Leiner; C. Schörgenhofer; P. Kalhs; A. Schulenburg; C. Sillaber; M. Mitterbauer; W. R. Sperr; U. Jäger; K. Skrabs; H. Greinix; A. Hermann; W. Lamm;
展开▼
作者单位

展开▼
年(卷),期 -1(142),-1
年度 -1
页码 1307–1314
总页数 8
原文格式 PDF
正文语种
中图分类外科学;
关键词
Hodgkin lymphoma Allogeneic HSCT Alemtuzumab-BEAM;

机译：霍奇金淋巴瘤;同种异体HSCT;Alemtuzumab-BEAM;

相似文献

外文文献
中文文献
专利

1. Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis [J] . Rabitsch W., Bojic M., Wohlfarth P., Journal of Cancer Research and Clinical Oncology . 2016,第6期

机译：Alemtuzumab-BEAM作为复发/难治性霍奇金淋巴瘤同种异体造血干细胞移植的条件：单中心分析
2. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. [J] . Sureda A, Robinson S, Canals C, Journal of Clinical Oncology . 2008,第3期

机译：在复发性或难治性霍奇金淋巴瘤中与常规同种异体干细胞移植相比，强度降低的条件：来自欧洲血液和骨髓移植小组淋巴瘤工作组的分析。
3. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era [J] . Mussetti A., Devlin S. M., Castro-Malaspina H. R., Bone marrow transplantation . 2015,第10期

机译：成人非复发性同种异体造血干细胞移植治疗复发性和难治性套细胞淋巴瘤：利妥昔单抗时代的单中心分析
4. Circulating Tumor DNA Predicts Post-Allogeneic Hematopoietic Stem Cell Transplantation in AML and MDS [C] . Sousuke Nakamura International Molecular Medicine Tri-Conference. . 2019

机译：循环肿瘤DNA预测AML和MDS中的同种异体造血干细胞移植
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study – a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation [O] . Anna Sureda, Carme Canals, Reyes Arranz, 2012

机译：复发或难治性霍奇金淋巴瘤患者降低强度条件后进行同种异体干细胞移植。 HDR-ALLO研究的结果–一项由GrupoEspañolde Linfomas / Trasplante deMédulaOsea（GEL / TAMO）和欧洲血液和骨髓移植小组淋巴瘤工作组进行的前瞻性临床试验
7. Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis [O] . W. Rabitsch, M. Bojic, P. Wohlfarth, 2016

机译：Alemtuzumab-BEAM作为复发/难治性霍奇金淋巴瘤同种异体造血干细胞移植的条件：单中心分析

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

摘要

著录项

相似文献

相关主题

期刊订阅